RALEIGH, N.C., Dec. 22 /PRNewswire/ -- Voyager Pharmaceutical Corporation announced Thursday its progress in enrolling subjects into the ALADDIN studies, Phase III Double-Blind, Placebo-Controlled trial investigating the safety and efficacy of VP4896 in the treatment of mild to moderate Alzheimer’s Disease.
A total of 64 sites are now enrolling subjects for the study. Fifty-three of the sites are located in the United States and Canada, with the remaining 11 in Australia. During the first two-and-a-half months of recruitment, these sites have enrolled 57 subjects.
“We are extremely pleased with the momentum of the ALADDIN study, and we are in fact ahead of schedule. Our sites are doing a great job and the early success makes me very optimistic for the future,” said Patrick Smith, the company’s president and CEO. “I am confident that the expertise and dedication of our clinical trial sites will help us meet our enrollment goals for the ALADDIN study.”
Voyager seeks to complete enrollment of 555 subjects in 2006.
Sites participating in the study are looking for participants who are 65 years or older with mild to moderate Alzheimer’s Disease and who have been taking Aricept(R), Exelon(R), Razadyne(TM) (formerly Reminyl(R)) or Cognex(R) for at least four months. People interested in the ALADDIN trial should go to http://www.clinicaltrials.gov and type in the search word “Aladdin” to obtain the most up-to-date information about the trial.
About VP4896 (Memryte)
VP4896 is a proprietary implantable form of leuprolide acetate developed by Voyager Pharmaceutical as a potential treatment for mild to moderate Alzheimer’s disease. VP4896 decreases the amount of luteinizing hormone (LH) released by the pituitary gland which, Voyager believes, may decrease or slow the progression of Alzheimer’s disease.
About Voyager Pharmaceutical Corporation
Voyager Pharmaceutical Corporation is a biopharmaceutical company focused on developing drugs for diseases associated with aging and development. Voyager’s scientific approach is based on the observation that many diseases of aging may be caused by changes in human reproductive hormone levels that are characteristic of the aging process. Voyager’s most advanced product candidate is Memryte, a proprietary, small, biodegradable implant that is comprised of leuprolide acetate and a polymer, that it is developing for the treatment of mild to moderate Alzheimer’s disease. Voyager was founded in 2001 and is headquartered in Raleigh, N.C.
Contact Information:
Steve Hamm, Director of Marketing
Office: 919-846-4880
Voyager Pharmaceutical Corporation
CONTACT: Steve Hamm, Director of Marketing of Voyager PharmaceuticalCorporation, +1-919-846-4880
Web site: http://www.clinicaltrials.gov/
